<DOC>
	<DOCNO>NCT00811395</DOCNO>
	<brief_summary>The primary objective evaluate long-term safety tolerability teriflunomide add treatment interferon-β [ IFN-β ] glatiramer Acetate [ GA ] patient multiple sclerosis [ MS ] relapse . Secondary objective evaluate long-term effect relapse rate , disability progression Magnetic Resonance Imaging [ MRI ] parameter . This study extension study PDY6045 ( NCT00489489 ) PDY6046 ( NCT00475865 ) study . Participants successfully complete initial study offer continue treatment ( compound , dose ) 24 additional week .</brief_summary>
	<brief_title>Long Term Safety Teriflunomide When Added Interferon-Beta Glatiramer Acetate Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The duration extension study per participant 40 week broken follow : - 24-week double-blind treatment period , - 16-week post-treatment elimination follow-up period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>PDY6045 PDY6046 participant : complete week 24 visit either study PDY6045 PDY6046 , still meet eligibility criterion receive treatment , agree continue stable dose Interferonβ [ IFNβ ] Glatiramer Acetate [ GA ] consent continue treatment . Any known condition circumstance would prevent investigator 's opinion , compliance completion study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>